CClinicalTrials.gg
RecruitingNCT06511284Updated Jul 19, 2024

Nutritional Therapy in Patients With Post-extubation Dysphagia

An interventional study of High protein dose and Usual protein dose in Dysphagia, sponsored by National Institute of Respiratory Diseases, Mexico. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by National Institute of Respiratory Diseases, Mexico · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the impact of the prescription of two doses of protein on the amount in kilograms of muscle mass and on the clinical evolution (time until safe swallowing, time until removal of the feeding stoma, number of hospital readmissions, feeding stoma infections, incidence of pneumonia, functionality, number of falls, fractures and mortality) at 6 months after hospital discharge in patients with enteral nutrition due to post-extubation dysphagia.

02

Conditions studied

  • Dysphagia

Browse trials for

Keywords

  • enteral nutrition
  • nutritional assessment
  • nutritional therapy
  • Deglutition Disorders
  • rehabilitation
03

In context

Deglutition Disorders

710 studies on the registry are indexed under Deglutition Disorders; 219 are open to participants now.

This study's planned enrollment of 128 is above the median of 60 across 471 interventional studies indexed under Deglutition Disorders.

Browse Deglutition Disorders studies →

Lead sponsor

National Institute of Respiratory Diseases, Mexico is the lead sponsor of 17 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who required invasive mechanical ventilation during their hospital stay with a diagnosis of post-extubation dysphagia diagnosed by fibroendoscopy evaluation of swallowing (FEES).
  • Patients who discharged with a feeding tube.
  • Patients with signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with pre-existing dysphagia, or with neurological conditions that can cause dysphagia (e.g. multiple sclerosis, Parkinson's disease, Alzheimer's, myasthenia gravis).
  • Patients with chronic kidney disease, defined as a glomerular filtration rate \<60 ml/min.
  • Patients discharged with a terminal condition and/or life expectancy of less than 3 months.
  • Diagnosis of HIV, upon receiving clinical follow-up by the team of specialists.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    High protein group

    100% of the energy requirements measured by indirect calorimetry (IC) or estimated, and a protein intake of 2.0 g/kg, will be prescribed

    Other: High protein dose

  • Other
    Usual protein group

    100% of the energy requirements measured by IC or estimated, and a protein intake of 1.5 g/kg, will be prescribed.

    Other: Usual protein dose

Interventions

  • OtherHigh protein dose

    High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition

  • OtherUsual protein dose

    Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition

06

What researchers measure

Primary outcomes

  1. Muscle mass changes

    Changes of muscle mass in kilograms measured by impedance bioelectric

    Time frame: From randomization to 6 months

Secondary outcomes

  1. Swallow recovery

    Time to safe swallowing diagnosed by fibroendoscopy evaluation of swallowing (FEES) and measured in months

    Time frame: From randomization to 6 months

  2. Duration of enteral nutrition indication

    Time from discharge to feeding tube removal

    Time frame: From randomization to 6 months

  3. Feeding tube complications

    Number of feeding tube infections, dysfunctions and oclusions during study period

    Time frame: From randomization to 6 months

  4. Muscle functionality changes

    Changes in functionality measured by medical research council scale in a scale of 0-60 points

    Time frame: From randomization to 6 months

  5. Handgrip strenght changes

    Changes in functionality assessed by handgrip strenght in kilogramos using a digital dynamometer

    Time frame: From randomization to 6 months

  6. Frailty complications

    Number of falls and fractures during study period

    Time frame: From randomization to 6 months

  7. Hospital readmissions associated to dysphagia complications

    Number of hospital readmissions assocciated to feeding tube infections, dysfunctions and oclusions during study period

    Time frame: From randomization to 6 months

  8. 6-month mortality

    All-cause mortality during study period

    Time frame: From randomization to 6 months

  9. Aspiration pneumonia incidence

    Number of hospital readmissions due to aspiration pneumonia

    Time frame: From randomization to 6 months

07

Study locations

1 of 1 sites recruiting
  • National Institute of Respiratory Diseases
    Mexico City, 14080, Mexico
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06511284
Lead sponsor
National Institute of Respiratory Diseases, Mexico
Responsible party
Ivan Armando Osuna Padilla (Clinical Nutrition Manager, National Institute of Respiratory Diseases, Mexico) — Principal investigator
First posted
Jul 19, 2024
Start date
Jul 1, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jul 19, 2024

Study contacts

Ivan A Osuna-Padilla, PhD
Contact
ivan.osuna@iner.gob.mx
+5216671035806
Alan Garcia-Grimaldo, MSc
Contact
agarciag1716@gmail.com
Ivan A Osuna-Padilla, PhD
principal investigator · National Institute of Respiratory Diseases

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion